Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q1 2016 · 10-Q
Revenue—
Net Income-$5.80M-$5.80MN/M vs Q1 2015 EPS Diluted-$0.13-$0.13N/M vs Q1 2015 Operating Income-$5,829,000N/M Operating Cash Flow-$3,142,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
ended Mar 31, 2016 · filed May 5, 2016 · 35 d after period end